|
CA2899363A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
|
JP2016505597A
(ja)
|
2012-12-21 |
2016-02-25 |
エピザイム，インコーポレイティド |
Ｐｒｍｔ５阻害剤およびその使用
|
|
CA2894126A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
|
DK2935222T3
(en)
|
2012-12-21 |
2019-01-07 |
Epizyme Inc |
PRMT5 INHIBITORS AND APPLICATIONS THEREOF
|
|
US9745291B2
(en)
|
2012-12-21 |
2017-08-29 |
Epizyme, Inc. |
PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
|
|
EP2970135B1
(en)
|
2013-03-14 |
2018-07-18 |
Epizyme, Inc. |
Pyrazole derivatives as prmt1 inhibitors and uses thereof
|
|
EP2970137A1
(en)
|
2013-03-14 |
2016-01-20 |
Epizyme, Inc. |
Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
|
|
WO2014153214A1
(en)
|
2013-03-14 |
2014-09-25 |
Epizyme, Inc. |
Arginine methyl transferase inhibtors and uses thereof
|
|
KR102028793B1
(ko)
|
2013-03-14 |
2019-10-07 |
에피자임, 인코포레이티드 |
아르기닌 메틸기 전이효소 억제제 및 이의 용도
|
|
WO2014153208A1
(en)
|
2013-03-14 |
2014-09-25 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
US9120757B2
(en)
|
2013-03-14 |
2015-09-01 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
WO2014144455A1
(en)
|
2013-03-15 |
2014-09-18 |
Epizyme, Inc. |
1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
|
|
CA2903813C
(en)
|
2013-03-15 |
2023-08-29 |
Epizyme, Inc. |
Carm1 inhibitors and uses thereof
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
WO2016022605A1
(en)
|
2014-08-04 |
2016-02-11 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2017070089A1
(en)
|
2015-10-19 |
2017-04-27 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
SG10202004618TA
(en)
|
2015-11-19 |
2020-06-29 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
|
MA44075A
(fr)
|
2015-12-17 |
2021-05-19 |
Incyte Corp |
Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
|
|
AU2016379372A1
(en)
|
2015-12-22 |
2018-08-02 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
AR108396A1
(es)
|
2016-05-06 |
2018-08-15 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
WO2017205464A1
(en)
|
2016-05-26 |
2017-11-30 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
HUE060256T2
(hu)
|
2016-06-20 |
2023-02-28 |
Incyte Corp |
Heterociklusos vegyületek mint immunmodulátorok
|
|
EP3484866B1
(en)
|
2016-07-14 |
2022-09-07 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
WO2018044783A1
(en)
|
2016-08-29 |
2018-03-08 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
US11160823B2
(en)
|
2016-11-07 |
2021-11-02 |
University Of Massachusetts |
Therapeutic targets for facioscapulohumeral muscular dystrophy
|
|
US20180179202A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
JP7101678B2
(ja)
|
2016-12-22 |
2022-07-15 |
インサイト・コーポレイション |
免疫調節剤としての複素環式化合物
|
|
LT3558990T
(lt)
|
2016-12-22 |
2022-12-27 |
Incyte Corporation |
Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai
|
|
ES2874756T3
(es)
|
2016-12-22 |
2021-11-05 |
Incyte Corp |
Derivados de triazolo[1,5-A]piridina como inmunomoduladores
|
|
WO2018119221A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Pyridine derivatives as immunomodulators
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
LT3483164T
(lt)
|
2017-03-20 |
2020-05-11 |
Forma Therapeutics, Inc. |
Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
US10745385B2
(en)
|
2017-05-25 |
2020-08-18 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
SMT202500157T1
(it)
|
2018-03-30 |
2025-05-12 |
Incyte Corp |
Composti eterociclici come immunomodulatori
|
|
HUE061503T2
(hu)
|
2018-05-11 |
2023-07-28 |
Incyte Corp |
Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
|
|
MX2021000887A
(es)
*
|
2018-08-01 |
2021-03-31 |
Araxes Pharma Llc |
Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
|
|
EP3852791B1
(en)
|
2018-09-19 |
2024-07-03 |
Novo Nordisk Health Care AG |
Activating pyruvate kinase r
|
|
EP3853206B1
(en)
|
2018-09-19 |
2024-04-10 |
Novo Nordisk Health Care AG |
Treating sickle cell disease with a pyruvate kinase r activating compound
|
|
JP2022539556A
(ja)
|
2019-06-28 |
2022-09-12 |
エイエルエス・セラピー・デベロップメント・インスティテュート |
ジペプチドリピートタンパク質の阻害
|
|
JP7665593B2
(ja)
|
2019-08-09 |
2025-04-21 |
インサイト・コーポレイション |
Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
|
|
HRP20251148T1
(hr)
|
2019-09-19 |
2025-11-21 |
Novo Nordisk Health Care Ag |
Pripravci koji aktiviraju piruvat-kinazu r (pkr)
|
|
PE20221038A1
(es)
|
2019-09-30 |
2022-06-17 |
Incyte Corp |
Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores
|
|
CA3160131A1
(en)
|
2019-11-11 |
2021-05-20 |
Incyte Corporation |
Salts and crystalline forms of a pd-1/pd-l1 inhibitor
|
|
JP2023518396A
(ja)
*
|
2020-03-18 |
2023-05-01 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
Ｃａｒｍ１の阻害によるがん治療法
|
|
TW202233615A
(zh)
|
2020-11-06 |
2022-09-01 |
美商英塞特公司 |
Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
|
|
CR20230230A
(es)
|
2020-11-06 |
2023-07-27 |
Incyte Corp |
Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo
|
|
WO2022099018A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Process of preparing a pd-1/pd-l1 inhibitor
|
|
US12128035B2
(en)
|
2021-03-19 |
2024-10-29 |
Novo Nordisk Health Care Ag |
Activating pyruvate kinase R
|